patients were reviewed to identify how antiplatelet therapy was managed in the perioperative period and any complications of care at the time of noncardiac surgery. The management of antiplatelet therapy extracted related to the cessation or continuation of aspirin or clopidogrel and the substitution of any other agents to reduce the likelihood of stent thrombosis. The complications of care specifically identified were cardiac ischaemic events on ECG; serum troponin rise; patients with a paclitaxel (Taxus Express) drugeluting stent inserted from December 1, 2002 to November 30, 2005 . All stents were inserted in compliance with the Victorian DHS guidelines 6 . The names of all patients with DES inserted at the Geelong Hospital were extracted from the cardiology database. The administrative database in the Division of Surgery was used to identify the patients with a drug-eluting stent inserted who had presented for non-cardiac surgery. The case notes of these 22 blood loss during surgery; operative conditions and bleeding complications noted in the surgical notes and re-operation for bleeding.
RESuLTS
Over a three-year period, 329 drug-eluting stents were inserted into 216 patients. Of these, 22 patients subsequently presented for a total of 42 non-cardiac surgical procedures. These procedures are summarised in Figure 1 .
In 14 patients, clopidogrel was ceased prior to non-cardiac surgery on 18 occasions. All these patients continued on aspirin when the clopidogrel was ceased. On one occasion wafarin was ceased and clopidogrel and aspirin were continued.
Four patients who ceased clopidogrel preoperatively, and were given other anti-thrombotic prophylaxis, did not suffer perioperative myocardial infarction or significant bleeding complications. Two were given prophylactic enoxaparin (1.5 mg/kg/day), two had tirofiban and heparin infusions 5 .
On 15 occasions patients did not receive alternative anti-thrombotic prophylaxis. Three of these patients (20%) suffered myocardial infarction in the perioperative period. All three patients survived.
One patient who remained on clopidogrel preoperatively suffered spontaneous gastrointestinal bleeding prior to laparotomy and subtotal colectomy for major uncontrolled haemorrhage and required further laparotomy for haemorrhage before discharge from hospital. The cases are reported here.
CASE 1
A 49-year-old male was scheduled for colonoscopy 630 days after having a paclitaxel drug-eluting stent inserted in his right coronary artery for management of an inferior myocardial infarction. Significant medical history included type 2 diabetes, asthma and hypercholesterolaemia. Clopidogrel was ceased five days prior to the planned procedure and he continued taking aspirin and his usual medications. One day prior to the planned procedure, he was admitted to hospital with an acute myocardial infarction. Angiography demonstrated acute stent thrombosis, a 90% left anterior descending coronary artery stenosis, a 70% stenosis of the left circumflex coronary artery and associated severe inferior hypokinesis. He required insertion of an intra-aortic balloon pump following angiography and was referred for emergency coronary artery bypass surgery. Peak serum troponin I level was 31.4 μg/l.
CASE 2
A 52-year-old male with tertiary hyperparathyroidism was scheduled for parathyroidectomy 197 days after insertion of a paclitaxel-eluting stent into his right coronary artery to treat an acute myocardial infarction. Significant medical history included polycystic kidney disease requiring bilateral nephrectomies and four years of haemodialysis, reflux oesophagitis, hypertension and hypercholesterolaemia. Surgery had been deferred to allow six months of clopidogrel treatment following stent insertion. He ceased clopidogrel one month prior to the surgery, but continued aspirin and his other medications. Preoperatively on the morning of his surgery he experienced chest pain, nausea, vomiting and associated sweatiness, but he did not inform his anaesthetist. His surgery proceeded with general anaesthesia lasting 105 minutes. No haemodynamic instability or ECG changes were noted intraoperatively. In the postoperative anaesthetic care unit he complained of chest tightness and nausea that was partially relieved by pethidine 50 mg, metoclopramide 20 mg and dolasetron 12.5 mg intravenously. His symptoms worsened and a 12-lead ECG showed 0.5 mm ST elevation in leads II, III and aVF, which settled with a GTN infusion. His serum troponin I level two hours after the operation was 11.4 μg/l. A serum troponin I level performed on blood taken six hours prior to surgery was <0.1 μg/l. A coronary angiogram performed a week later demonstrated in-stent thrombosis of the DES in the right coronary artery. Echocardiography showed new mid-basal akinesis. He was managed with medical therapy.
CASE 3
A 55-year-old man was scheduled for subacromial decompression for shoulder impingement 520 days after insertion of a paclitaxel-eluting stent into his right coronary artery to manage angina refractory to medical therapy. Significant medical history included obstructive sleep apnoea and chronic back pain. Clopidogrel was ceased two weeks prior to the planned surgery but aspirin therapy was continued. One week prior to the planned surgery he developed severe chest pain and was diagnosed with acute inferior myocardial infarction. Emergency angiography showed acute in-stent thrombosis of the DES. He was treated with intracoronary abciximab and aspiration of thrombus followed by an intravenous abciximab infusion. This was complicated by multiple episodes of ventricular fibrillation requiring cardioversion, amiodarone infusion and insertion of an intra-aortic balloon pump. A follow-up angiogram four months later showed his stent to be patent and normal left ventricular function. The peak troponin level was 29.1 μg/l.
CASE 4
A 59-year-old man presented with severe rectal bleeding at a rural hospital, 40 days after paclitaxeleluting stent insertion to manage refractory angina. Emergency colectomy and ileostomy formation were performed prior to transfer to our institution. He was given 21 units of packed red blood cells, fresh frozen plasma, platelets and three units of whole blood prior to transfer. On admission he was found to have bleeding from a peritoneal drain, a temperature of 35.4°C, haemoglobin level 48 g/l, platelet count 105×10 9 /l, INR 1.4, activated partial thromboplastin time 34 s and fibrinogen leve1 1.6 g/l. At repeat laparotomy, large clots and free blood were found but no major bleeding source apart from two oozing areas in each iliac fossa, which were controlled with packs. He was transfused a further four units of packed red blood cells and five units of fresh frozen plasma in theatre. Bleeding settled postoperatively and clopidogrel and aspirin were restarted after three days. There was no evidence of myocardial ischaemia on ECG performed on day two and serum troponin I levels were normal on postoperative days one and three.
DISCuSSION
Percutaneous coronary intervention has become the recommended therapy for treating occlusive coronary disease and projected estimates predict worldwide rates of percutaneous coronary intervention will increase to 3000 per million in the next five years 1 . Drug-eluting stents are rapidly replacing the use of bare metal stents, both for angina and the management of acute coronary syndromes. up to 80% of coronary stents placed in the united States are drug-eluting stents, with some centres using them exclusively 7 . The rate of re-stenosis due to neointimal hyperplasia requiring further intervention has been reduced dramatically compared with bare metal stents. However, delayed re-endothelialisation with DES results in an increased risk of late stent thrombosis 8, 9 . About 1.3% of patients with drug-eluting stents inserted develop stent thrombosis, while premature discontinuation of antiplatelet therapy carries a much increased risk of myocardial infarction with a case fatality rate of 30 to 45% 10, 11 . The most important predictor of late stent thrombosis is antiplatelet drug withdrawal 10 . Diabetes, renal failure, duration of stent placement, small reference vessel diameter, complex lesions, low ejection fraction, local hypersensitivity reactions, position of the stent relative to plaque, type and dose of antimitotic agent have also been identified as contributory factors 8, [10] [11] [12] [13] . The fact that drug-eluting stents present additional risk over bare metal stents is exemplified by reports of angiographic data from patients with both types of stents 14, 15 . Thrombosis occurred only in the drug-eluting stents, but not bare metal stents, more than one year after withdrawal of antiplatelet agents.
In our observational study we found a 21.4% myocardial infarction rate in patients who ceased clopidogrel prior to non-cardiac surgery and were not given any other anti-thrombotic prophylaxis. There are important features of these episodes that are worth emphasising.
All infarcts occurred more than six months after stent insertion (seven, 18 and 22 months).
All patients remained on aspirin and still suffered myocardial infarction. The protective effect of aspirin does not appear to endure with paclitaxel drug-eluting stents. Two of the myocardial infarcts occurred within five days of ceasing clopidogrel. This suggests that alternative effective therapy must be started before five days have elapsed following cessation of clopidogrel prior to non-cardiac surgery. Two myocardial infarcts occurred preoperatively. The third in retrospect had symptoms on the day of surgery, suggesting the infarct was evolving preoperatively. This implies that the degree of surgical insult is not of primary importance in the determination of perioperative outcomes with DES. All myocardial infarcts were in the territory of a drug-eluting stent in the right coronary artery. The exact significance of this observation is not clear and requires further observational studies to confirm the significance of a right coronary artery stent thrombosis after ceasing clopidogrel for non-cardiac surgery. Late stent thrombosis is defined as in-stent thrombosis occurring greater than six months after drug-eluting stent insertion. Late stent thrombosis is associated with withdrawal of antiplatelet agents, often in the perioperative period, and may occur up to 26 months after drug-eluting stent insertion 7, [16] [17] [18] [19] . Further studies have led to 1.
2.
3.
4.

5.
recommendations that patients continue their antiplatelet agents for periods longer than the original recommendation of three to six months 20 .
The use of drug-eluting stents, with the need for prolonged antiplatelet drug administration, illustrates the balance that needs to be maintained between myocardial ischaemia and bleeding complications 2, 5, 14, 15, 21 . This highlights the need for clear and explicit protocols in the management of these patients in the perioperative period 2,5,22,23 .
We have previously described a management guideline for these patients, which avoided the complication of myocardial infarction in three patients 5 .
understanding the risk of myocardial infarction or bleeding in the setting of non-cardiac surgery with drug-eluting stents present in the coronary circulation is an important factor in deciding appropriate management of these patients.
We observed that only one patient in the group presenting for non-cardiac surgery had suffered catastrophic bleeding. This suggests that the dangers of bleeding, occurring during non-cardiac surgery, when patients remain on clopidogrel are much less common than the dangers of myocardial infarction, in the territory of the drug-eluting stent, occurring as a result of cessation of clopidogrel treatment prior to non-cardiac surgery.
In the patients reviewed 14 surface or minor procedures were carried out while patients remained on clopidogrel and these patients suffered no recorded bleeding complications. There were three major emergency procedures (femoro-femoral bypass; right hemicolectomy; vitrectomy) performed while patients were still taking clopidogrel and aspirin where bleeding problems were not encountered.
There is a paucity of data relating to the risk of perioperative bleeding in patients taking clopidogrel presenting for non-cardiac surgery. The CuRE trial demonstrated a 1% per year excess of major non-surgical bleeding compared to placebo 24 . For patients having cardiac surgery, clopidogrel presents a major bleeding risk. When given with aspirin prior to coronary surgery patients are 10 times more likely to require re-operation for bleeding 25 . When clopidogrel was taken within four days of cardiac surgery, mediastinal drain losses were doubled, blood transfusions dramatically increased, as were re-operation for bleeding and length of ICu stay 26 .
Cessation of clopidogrel prior to non-cardiac surgery in patients with drug-eluting stents implanted in the coronary circulation exposes these patients to a significant risk of myocardial infarction in the territory of the stent as little as four days after ceasing clopidogrel. Myocardial infarction can occur before surgery commences. This risk may be reduced by the use of either enoxaparin or a glycoprotein IIb, IIIa inhibitor and heparin infusion prior to surgery, but numbers in our observational study are low.
We would suggest that a large multi-centre, prospective observational study be commenced in patients undergoing non-cardiac surgery after insertion of a DES in the coronary circulation to address the issue of optimal replacement of clopidogrel prior to non-cardiac surgery in such patients.
until such a study is collecting data we would invite anaesthetists to document patients with DES via a website specifically designed to collect the clinical and technical details required to inform practice in this area. We have set up such a website with the approval of the Australian and New Zealand College of Anaesthetists Clinical Trials Group at http://DESreporting.com and are collecting formatted data from centres worldwide.
